- ISIN
- IE00B4Q5ZN47
- CUSIP
- 00B4Q5ZN4
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 1, 2007
Highlights
- Market Cap
- $14.93B
- Enterprise Value
- $15.20B
- EPS (TTM)
- $0.47
- PE Ratio
- 478.54
- PEG Ratio
- 31.11
- Total Revenue (TTM)
- $4.44B
- Gross Profit (TTM)
- $2.97B
- EBITDA (TTM)
- $336.83M
- Year Range
- $105.00 - $243.32
- Target Price
- $216.14
- ROA (TTM)
- 0.25%
- ROE (TTM)
- 0.65%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
JAZZ Performance Chart
Jazz Pharmaceuticals plc (JAZZ) is up 32.9% since the beginning of the year. At $226 per share, JAZZ is trading 7.2% below its 52-week high of $243. Investors who bought $1,000 worth of JAZZ shares 5 years ago would now be looking at an investment worth $1,276.
Loading charts...
Returns By Period
Jazz Pharmaceuticals plc (JAZZ) has returned 32.89% so far this year and 110.14% over the past 12 months. Over the last ten years, JAZZ has returned 5.06% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Jazz Pharmaceuticals plc
- 1D
- 0.56%
- 1M
- -5.80%
- YTD
- 32.89%
- 6M
- 33.15%
- 1Y
- 110.14%
- 3Y*
- 21.86%
- 5Y*
- 5.00%
- 10Y*
- 5.06%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
JAZZ Monthly Returns History
Based on dividend-adjusted daily data since Jun 1, 2007, JAZZ's average daily return is +0.14%, while the average monthly return is +2.71%. At this rate, an investment would double in approximately 2.2 years.
Historically, 52% of months were positive and 48% were negative. The best month was Jun 2009 with a return of +270.0%, while the worst month was Jan 2009 at -50.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, JAZZ closed higher 50% of trading days. The best single day was Jun 10, 2009 with a return of +209.8%, while the worst single day was Nov 12, 2008 at -40.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.24% | 15.52% | -0.51% | 7.39% | 16.49% | -4.47% | 32.89% | ||||||
| 2025 | 0.99% | 15.41% | -13.50% | -5.79% | -7.60% | -1.80% | 8.02% | 11.45% | 3.17% | 4.43% | 28.25% | -3.70% | 38.04% |
| 2024 | -0.23% | -3.11% | 1.28% | -8.03% | -4.97% | 1.41% | 3.30% | 5.20% | -3.94% | -1.24% | 10.51% | 1.28% | 0.12% |
| 2023 | -1.66% | -10.38% | 4.22% | -4.00% | -8.76% | -3.27% | 5.20% | 9.92% | -9.71% | -1.87% | -6.92% | 4.03% | -22.79% |
| 2022 | 9.03% | -1.07% | 13.28% | 2.92% | -6.58% | 4.23% | 0.03% | -0.54% | -14.13% | 7.88% | 9.12% | 1.53% | 25.05% |
| 2021 | -5.79% | 8.06% | -2.18% | 0.02% | 8.35% | -0.28% | -4.57% | -22.30% | -1.14% | 2.17% | -9.90% | 6.28% | -22.81% |
Benchmark Metrics
Jazz Pharmaceuticals plc has an annualized alpha of 26.76%, beta of 1.12, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 01, 2007.
- This stock captured 155.68% of S&P 500 Index gains and 123.77% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 26.76%
- Beta
- 1.12
- R²
- 0.09
- Upside Capture
- 155.68%
- Downside Capture
- 123.77%
Return for Risk
Risk / Return Rank
JAZZ ranks 96 for risk / return — in the top 96% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Jazz Pharmaceuticals plc (JAZZ) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JAZZ | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.95 | ||
| Sortino ratioReturn per unit of downside risk | +1.78 | ||
| Omega ratioGain probability vs. loss probability | 1.57 | 1.37 | +0.20 |
| Calmar ratioReturn relative to maximum drawdown | 9.70 | 2.78 | +6.92 |
| Martin ratioReturn relative to average drawdown | 24.16 | 12.44 | +11.72 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Jazz Pharmaceuticals plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Jazz Pharmaceuticals plc was 96.90%, occurring on Apr 23, 2009. Recovery took 408 trading sessions.
The current Jazz Pharmaceuticals plc drawdown is 5.89%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Financial crisis2007–2009 | -96.90%Apr 2009 | 1y 10mo | 1y 7mo | 3y 6moJun 2007 - Dec 2010 |
COVID crash2020 | -54.54%Mar 2020 | 4y 7mo | 5y 11mo | 10y 7moJul 2015 - Feb 2026 |
2014 bear market2014 | -28.77%Apr 2014 | 1mo 10d | 7mo 23d | 9mo 3dFeb 2014 - Nov 2014 |
2011 bear market2011 | -25.64%Nov 2011 | 1mo 19d | 2mo 1d | 3mo 20dSep 2011 - Jan 2012 |
2011 bear market2011 | -23.17%May 2011 | 1mo 6d | 1mo 8d | 2mo 14dApr 2011 - Jul 2011 |
Drawdown Indicators
| JAZZ | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.90% | -56.78% | -40.12% |
Max Drawdown (1Y)Largest decline over 1 year | -11.42% | -9.10% | -2.32% |
Max Drawdown (3Y)Largest decline over 3 years | -32.71% | -18.90% | -13.81% |
Max Drawdown (5Y)Largest decline over 5 years | -47.09% | -25.43% | -21.66% |
Max Drawdown (10Y)Largest decline over 10 years | -52.10% | -33.92% | -18.18% |
Current DrawdownCurrent decline from peak | -5.89% | -1.80% | -4.09% |
Average DrawdownAverage peak-to-trough decline | -27.35% | -10.71% | -16.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.58% | 2.03% | +2.55% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Jazz Pharmaceuticals plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Jazz Pharmaceuticals plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for JAZZ, comparing it with other companies in the Biotechnology industry. Currently, JAZZ has a P/E ratio of 478.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for JAZZ compared to other companies in the Biotechnology industry. JAZZ currently has a PEG ratio of 31.1. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for JAZZ relative to other companies in the Biotechnology industry. Currently, JAZZ has a P/S ratio of 3.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for JAZZ in comparison with other companies in the Biotechnology industry. Currently, JAZZ has a P/B value of 3.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with JAZZ
Add Jazz Pharmaceuticals plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with JAZZ